Investor · 9 deals
Every published round Gates Foundation took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Gates Foundation has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Aphea.Bio | Jul 2023 | 1 | 0 | |
| Atomo Diagnostics | 2016, Grant | 1 | 0 | |
| ENA Respiratory | Antiviral nasal spray to prevent severe respiratory viral infections | 22 Oct 2025, Series B | 1 | 0 |
| Nbryo | Nov 2025, Grant | 2 | 0 | |
| Nybro | 19 Aug 2026, Seed | 1 | 0 | |
| PlasmaLeap Technologies | Modular plants for local production of fertilisers and fuels | 2026, Series A | 2 | 2 |
| Vaxxas | 18 Mar 2020, Grant | 1 | 1 |
Fund closes reported for Gates Foundation, as distinct from the investments it has made.
Companies Gates Foundation has backed that another company then bought. An exit for the holding, not a deal Gates Foundation did.
Stories naming Gates Foundation. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
A Sydney condom medtech is preparing a capital raise via an advisory firm; its earlier backers include a foundation and a startup co-founder, per the article.
Brandon Capital has put roughly $60 million of National Reconstruction Fund money into ten biotech companies and warns R&D tax changes would hurt deep tech; portfolio company Myricx Bio went to Novartis.
Also australiatimes.com
Profile of a Sydney-based medical device maker developing a hydrogel condom, noting its human safety trial, manufacturing build-out, patent portfolio and grant backing.
Weekly roundup: Constantinople raises $62.5m; Blackbird wraps fund six above $1b; Guardhouse buys Mobohubb; SCX.ai debuts on the ASX; plus seed rounds, exits and executive changes across the ecosystem.
Roundup of seven raises across the Tasman spanning fintech, marine tech, agtech, defence and AI, plus a first close for an ACT venture fund.
A Queensland livestock-reproduction startup has grown its seed round to $20 million, drawing $2 million from a newly launched state government fund whose manager had already backed the company.
Queensland agtech startup Nybro, working on beef genetics via reproductive technologies, raised a $20 million Seed round with QIC Ventures leading and the Gates Foundation participating, per Startup Daily.
Also Startup Daily
Roundup of four Australian raises: Firmus Technologies' US$2 billion round at a $15 billion valuation, Eudaemon's $3.75 million, Zabidou's $3.5 million seed round, and Rampart's $2.3 million.
Sydney cleantech PlasmaLeap raised a US$20m Series A to build fertiliser hubs and expand green ammonia reactor technology for farmers.
Melbourne-based ENA Respiratory announced US patent allowances covering its TLR2 agonist platform and a COPD treatment method, strengthening IP protection for its INNA-051 nasal spray candidate now in Phase II testing.
GrainCorp's venture arm has joined a Series A backing PlasmaLeap Technologies, an Australian maker of modular on-farm fertiliser systems, which will use the funds for its first hubs in NSW and Tasmania.
A weekly roundup detailing new funding rounds for six Australian startups: Lyka, PlasmaLeap, Firmable, Veyor, Lumonus and Future Minds Network, with investors and round details.
PlasmaLeap, a Sydney maker of emissions-free fertiliser technology, has closed a US$20m Series A backed by Gates Foundation, Investible, Yara Growth Ventures and other investors.
Melbourne biotech ENA Respiratory has begun dosing volunteers in a mid-stage trial of its INNA-051 antiviral spray, aimed at limiting common viral illnesses in at-risk groups.
Roundup of eight funding deals: Synchron's Series D, plus raises by Lumonus AI, Hullbot, Nbryo, Cytophenix, Giftbee, Understanding Zoe and Zeligate, spanning medtech, robotics, agtech and AI.
Also Startup Daily·Startup Daily·Startup Daily·Startup Daily·SmartCompany·Startup Daily·Startup Daily
Cattle genetics startup Nbryo has landed $10 million co-led by Tenacious Ventures and AgriZeroNZ, plus an $18 million research grant, to commercialise its embryo technology.
Also Beef Central / Grain Central·SmartCompany·Startup Daily·nbryo.com·nbryo.com
Queensland cattle-breeding biotech Nbryo has secured $10m in seed backing co-led by Tenacious Ventures and AgriZeroNZ, alongside an $18m research grant from the Gates Foundation and Meat and Livestock Australia.
Also SmartCompany·Beef Central / Grain Central·AgFunderNews·SmartCompany·Startup Daily·nbryo.com
Nbryo closed a A$10 million round co-led by Tenacious Ventures with AgriZeroNZ, QIC, the Murdoch family and Mandalay, and has drawn over $18 million in grants from Gates Foundation and Meat and Livestock Australia.
Weekly funding roundup covering eight raises totalling over $113 million across aerospace, biotech, materials, health and software, plus a pharmacy firm's acquisition out of administration.
Weekly roundup of eight trans-Tasman startup raises worth a combined $113 million-plus, alongside Joe Zhou's buyout of StrongRoom AI from administrators.
Vaxxas announced a roughly A$90m financing — Series D equity led by SPRIM Global Investments plus debt — to advance its needle-free vaccine patch, alongside leadership changes including a new chair.
Drone delivery company Swoop Aero has entered voluntary administration after its cofounder blamed investor pressure; administrators now seek a buyer or recapitalisation. The piece recalls its 2021 Series B and 2018 Startmate stint.
Also Startup Daily
Aura's column traces family offices' rise into major capital players, their philanthropy and succession challenges, and notes the closure of its Shippit co-investment vehicle plus Dan Annan's appointment as Distribution Director.
Tenacious Ventures' investment note explains its backing of Nbryo, an Australian startup speeding genetic improvement in beef and dairy via embryo technologies, and notes research funding from MLA and the Gates Foundation.
A year-end countdown of 2023's twenty largest agtech funding rounds, from biofuels and carbon marketplaces to farm robotics, with EcoCeres' $400 million raise at the top.
Also AgFunderNews
Vaxxas reports positive Phase I results for its needle-free skin-patch delivery of a measles-rubella vaccine, with Gates Foundation grant funding and a planned PATH-sponsored Phase I/II trial in The Gambia.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·SmartCompany·labonline.com.au
AgFunder's Asia-Pacific investment analysis finds agriculture-focused biotech surged in 2022, with China and India ahead, while Australian soil-carbon firm Loam Bio landed a sizable round in 2023.
Also AgFunderNews
Weekly agrifoodtech roundup: Paine Schwartz closes its $1.7bn food-and-ag fund; several seed and Series A rounds; Tangelo acquires Diet ID; Infarm declared bankrupt; layoffs and partnerships across the sector.
Brisbane vaccine patch maker Vaxxas won a $5.4 million Wellcome grant for studies and a Phase I trial of a typhoid vaccine using its HD-MAP technology, developed with SK bioscience.
Weekly agrifoodtech roundup reporting numerous funding rounds including Aphea.Bio, Bobbie and Sensand, a Coca-Cola-backed venture fund close, Do Good Foods' bankruptcy filing, and The Andersons acquiring Bridge Agri Partners.
Also AgFunderNews
Vaxxas, with Queensland Government backing, has opened its Brisbane global headquarters and vaccine patch manufacturing facility, supported by state and federal government funding.
Vaxxas reports encouraging interim Phase I results for its needle-free microarray-patch COVID-19 vaccine, with strong antibody responses and no serious adverse events, ahead of planned regulatory applications in Australia and the US.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·SmartCompany·labonline.com.au
Vaxxas hires former Pfizer medical executive Dr Rochelle Chaiken as its chief medical officer; the announcement also recounts the biotech's founding financing and later rounds.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·SmartCompany·labonline.com.au
Vaxxas has appointed 23-year Pfizer veteran Dr Rochelle Chaiken as chief medical officer; the announcement also recaps the vaccine-patch company's early backing by OneVentures, Brandon Capital and others.
Vaxxas completed a US$23 million (A$34 million) financing led by OneVentures and UniQuest to advance its needle-free vaccine clinical programs, including a COVID-19 candidate, with board members, management and individual investors also participating.
Also Brandon Capital portfolio·OneVentures portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·SmartCompany·SmartCompany·Techboard·labonline.com.au·@AuManufacturing·@AuManufacturing
Vaxxas has begun a phase one trial in Australia of its needle-free COVID-19 vaccine patch. The Brisbane company, backed by OneVentures, Brandon Capital and others, has hired Scott Fry from Ellume as COO.
Brisbane biotech Vaxxas has begun human testing of its microneedle patch for COVID-19 vaccination and plans a phase two study; the venture-backed company has raised over $66 million.
Pfizer has completed its takeover of ASX-listed telehealth diagnostics company ResApp Health for $179 million, with the article recalling the company's 2015 listing, earlier raises and a Gates Foundation grant.
Pfizer has completed its purchase of Brisbane digital health company ResApp Health for $179 million, doubling its per-share offer after an April bid for the ASX-listed cough-diagnosis startup.
Also SmartCompany·Startup Daily·Startup Daily·Techboard·Startup News (WA)·sharecafe.com.au